Meta Pixel

News and Announcements

Industrial property investment opportunity with attractive yield and IRR

  • Published February 09, 2021 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

EG is pleased to provide you with an opportunity to consider the EG Vineyard Property Trust Information Memorandum.

The property is a 4.8 Ha multi-tenanted industrial property located at 172 Commercial Road, Vineyard NSW. Vineyard is a suburb in north-western Sydney, situated 50km north-west of the Sydney CBD.

EG has secured the Property on an attractive 7.0% initial yield, which has been achieved by restructuring and renegotiating the leases on the Property during the Due Diligence period. At acquisition, the property will comprise 9 tenants with a WALE of approximately 3.4 years. The Property has a vacancy of 9%, and on a fully leased basis would show a yield of approximately 7.7%.  Cash distributions are forecast to average 8.25% p.a. over the 3-year term, with a projected IRR of 16.5% p.a.

Register Interest

About EG Private Wealth

EG grows the wealth of our private investors through commercial property syndication opportunities. Achieving consistent, above-average returns and capital security, EG takes a personalised and aligned approach to every opportunity.

As a team, we have invested over $250 million of private wealth in the property sector, achieving an average 27.8% IRR. The team you meet at the outset is the team who you will work with throughout the lifecycle of your investment, providing you with hands on, personalised service at every stage.

EG is committed to utilizing property technology to uncover new opportunities and to enhance returns for investors. Our proprietary risk assessment model clearly measures and prices real estate risks, providing a disciplined, data-led approach to decision making.

Our investors include sophisticated wholesale investors, trusts, SMSFs and companies who want investments that deliver strong yields and potential for capital growth in the medium to long term.

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now